Literature DB >> 10605521

Persistent hyperinsulinaemic hypoglycaemia of infancy (nesidioblastosis): a report from Kuwait.

D G Ramadan1, M H Badawi, M Zaki, Z el Mazidi, E A Ismail, H el Anzi.   

Abstract

We report nine Bedouin children from Kuwait with persistent hyperinsulinaemic hypoglycaemia (PHHI) seen over a 13-year period in two regional hospitals. The incidence of PHHI in this inbred community is high (1:20,000); five of them came from two families. All the children presented with seizures associated with severe and recurrent hypoglycaemia, eight presenting in the neonatal period and one at the age of 2 months. One child died soon after birth. All the others received diazoxide initially, which achieved remission in one while two siblings remain dependent on the drug. Long-acting somatostatin analogue (octreotide) was successfully used in one child. Four children underwent pancreatectomy, two showed diffuse and two had localized nesidioblastosis. Two children achieved normal neurodevelopmental milestones, four suffered mental retardation of varying degrees and three died. Early diagnosis and prompt treatment are essential to avoid the neurological damage associated with hypoglycaemia. In some cases, this condition is due to an autosomal recessive pattern of inheritance and it is therefore important to offer genetic counselling to families with one or more affected siblings.

Entities:  

Mesh:

Year:  1999        PMID: 10605521     DOI: 10.1080/02724939992644

Source DB:  PubMed          Journal:  Ann Trop Paediatr        ISSN: 0272-4936


  2 in total

1.  Using referral rates for genetic testing to determine the incidence of a rare disease: The minimal incidence of congenital hyperinsulinism in the UK is 1 in 28,389.

Authors:  Daphne Yau; Thomas W Laver; Antonia Dastamani; Senthil Senniappan; Jayne A L Houghton; Guftar Shaikh; Tim Cheetham; Talat Mushtaq; Ritika R Kapoor; Tabitha Randell; Sian Ellard; Pratik Shah; Indraneel Banerjee; Sarah E Flanagan
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240

Review 2.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.